Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and ...

Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits ...

By bringing Exact Sciences into the fold, the expectation is that the focus on cancer diagnostics can provide a jolt to the ...

In a landmark move, Abbott announced on Thursday its plan to acquire cancer test manufacturer Exact Sciences for an estimated $23 billion. This acquisition marks one of Abbott's most significant deals ...

Exact Sciences markets Cologuard as a non-invasive, convenient test. The traditional method of testing for colorectal cancer ...

The second-most common cancer in Malaysia may not have symptoms, which is why experts advocate checkups for early detection.

The age that bowel cancer screening starts in the Channel Islands should be lowered according to someone who has the disease.

Abbott Laboratories to acquire cancer diagnostics company for $105 per share in deal valued at $21 billion. Closing expected Q2 2026.

Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of ...

Business Insider's exclusive analysis shows colon cancer in your 30s can cost $45,000 in one year alone. We break it down, ...